Skip to main content
Top
Published in: Journal of Clinical Immunology 2/2013

01-01-2013

Overview of Routes of IgG Administration

Author: Troy R. Torgerson

Published in: Journal of Clinical Immunology | Special Issue 2/2013

Login to get access

Abstract

The use of exogenous serum to provide protection against infections began more than a century ago. Over time, this concept matured and led to the preparation of concentrated immunoglobulin (IgG) products that were safe and effective when delivered subcutaneously (SC) or intramuscularly (IM) but were not ideal for intravenous (IV) use. Continued improvements led to the development of IgG preparations that are safe for either subcutaneous IgG (SCIG) or intravenous IgG (IVIG) delivery and allow providers and patients significant flexibility to develop an effective but manageable treatment plan. Factors that influence the choice of IgG product and delivery method can maximize the therapeutic benefit and provide the best possible quality of life for patients.
Literature
1.
go back to reference Behring V. Uber das Zustandekommen der Diphterie–Immunitat und der Tetanus–Immunitat bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.CrossRef Behring V. Uber das Zustandekommen der Diphterie–Immunitat und der Tetanus–Immunitat bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.CrossRef
2.
go back to reference Berger M. A history of immunoglobulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368–78.PubMedCrossRef Berger M. A history of immunoglobulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368–78.PubMedCrossRef
3.
go back to reference Janeway CA. The development and clinical uses of immunoglobulins: a review. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington DC: National Academy of Sciences; 1970. p. 3–14. Janeway CA. The development and clinical uses of immunoglobulins: a review. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington DC: National Academy of Sciences; 1970. p. 3–14.
4.
5.
go back to reference Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.PubMed Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.PubMed
6.
go back to reference Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRef Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRef
Metadata
Title
Overview of Routes of IgG Administration
Author
Troy R. Torgerson
Publication date
01-01-2013
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue Special Issue 2/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9845-2

Other articles of this Special Issue 2/2013

Journal of Clinical Immunology 2/2013 Go to the issue